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Abstract: Pyocyanin has recently emerged as an important virulence factor produced by
Pseudomonas aeruginosa. The redox-active tricyclic zwitterion has been shown to have a number
of potential effects on various organ systems in vitro, including the respiratory, cardiovascular,
urological, and central nervous systems. It has been shown that a large number of the effects to
these systems are via the formation of reactive oxygen species. The limitations of studies are, to date,
focused on the localized effect of the release of pyocyanin (PCN). It has been postulated that, given its
chemical properties, PCN is able to readily cross biological membranes, however studies have yet
to be undertaken to evaluate this effect. This review highlights the possible manifestations of PCN
exposure; however, most studies to date are in vitro. Further high quality in vivo studies are needed
to fully assess the physiological manifestations of PCN exposure on the various body systems.
Keywords: inflammation; oxidative stress; Pseudomonas aeruginosa; pyocyanin; virulence factor
1. Introduction
Pseudomonas aeruginosa is a Gram-negative bacterium responsible for severe nosocomial infections
in a number of body systems including the respiratory tract, the vascular system, the urinary tract,
and the central nervous system (CNS) [1–7]. It has been well documented that P. aeruginosa produces
a number of secreted virulence factors known as phenazines. One such compound is pyocyanin
(PCN) [8] which has been widely studied to date and is emerging as a virulence factor of interest given
the antimicrobial resistant, chronic nature of pseudomonal infections [9].
PCN is a nitrogen-containing aromatic compound belonging to the tricyclic phenazine class of
compounds [8,10–15] as seen in Figure 1. PCN is a zwitterion [8,14,16] containing a phenol group,
giving it weak acidic characteristics (pKa of 4.9) [10,12,17,18]. At physiological pH, PCN exists
in its ionized, neutral state (blue) and in its protonated, charged form (red) when in an acidic
environment [8,16,18]. The low molecular weight and zwitterionic properties of PCN are believed
to permit the toxin to easily permeate cell membranes [8,14,16]. Despite this reported ability to cross
biological membranes, the presence of PCN in systemic circulation has yet to be reported. In light of
this, reports on the levels of PCN are limited to the compartments directly associated with infection.
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PCN is secreted by P. aeruginosa into the local environment by a type II secretion system [19]. Significant
levels of PCN have been detected in sputum sol (up to 130 µM), ear secretions (up to 2.7 µM), wounds
(up to 8.1 µM), and urine following chronic infection by P. aeruginosa [20–22]. These values indicate
the possible relevance of this virulence factor in the pathophysiology of pseudomonal infections and
possible toxic effects in the biological systems where the infection is located. Further studies are needed
to evaluate the diffusibility of this molecule in both in vitro and in vivo studies.
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To date, numerous studies have shown the potential importance of PCN in the virulence
and pathogenici y of pseudomonal infections and its potential toxic effects [14,23,24]. PCN has
b en hown to have numerous antagonis ic e fects on the host, both in vivo and in vitro, including
pro-inflammatory nd free rad cal eff cts resulting in cellular damage a d death [23,25–27]. Given the
high ncidence of chronic colonization with P. aeruginosa n cystic fibrosis (CF), the majority of research
on PCN to date has primarily been focused on its effect on human airway. However, recently here
have been a number of studi s demonstrating the bro der consequences of PCN exposure, especially in
the urinary tract [27,28], the cardiovascular syst m [29], and the CNS [30,31]. In light of this, th focus
of the review is to highlight the diverse cellular effects of PCN in vitro, in vivo nd in humans.
This review highlights the importance of PCN in not only the pathophysiology of pseudomonal lung
disease but als in the pseudomonal infections of other organ systems.
2. Role of Oxidative Stress in Pyocyanin’s Toxicity
Oxidative stress is a major contributing factor to the cytotoxicity displayed by PCN [32,33],
a reversible redox-active compound with its effects seen in Figure 2 below [8,12,17,18,21,34]. PCN’s
induction of oxidative stress is, at least in part, due to its ability to increase intracellular levels of
reactive oxygen species (ROS), in particular superoxide (O2¨´) [10–12,17,25,34,35] and hydrogen
peroxide (H2O2) [25,36]. These increases are mediated by dismutase and under aerobic conditions,
H2O2 and O2¨´ and are formed by cyclic non-enzymatic reduction by NAD(P)H [12,17,34] with
PCN accepting electrons from NAD(P)H [10–12]. The intracellular ROS formed after PCN exposure
cause free radical damage resulting in oxidative damage to components of the cell cycle, as well as
direct damage to DNA [17,37], NAD(P)H depletion and enzyme inhibition [17] with the main target,
the mitochondria of cells [38].
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In further support of the integral role of oxidative stress in PCN’s ability to induce cytotoxicity, it
has been demonstrated that strains of P. aeruginosa that overproduce PCN produce greater levels of
oxidative stress, subsequent cell lysis, and a significant increase in extracellular DNA (eDNA) [40].
To further enhance the virulence of P. aeruginosa, through an oxidative stress-dependent mechanism,
PCN has then been shown to intercalate with eDNA to promote cell-to-cell interactions between
P. aeruginosa cells by influencing their cell surface properties and physicochemical interactions. It has,
therefore, been suggested that PCN may also contribute to biofilm formation by the promotion of
eDNA [40]. This study highlights the fact that not only does PCN-induced oxidative stress result in
direct cellular damage and death, but also in the persistence of infections caused by P. aeruginosa via
the above mechanism.
Infection by P. aeruginosa, and subsequent secretion of PCN, has been shown to have a dramatic
effect on the cellular protective mechanisms of the enzymes superoxide dismutase (SOD), catalase
(CAT), and glutathione peroxidise (GSH-Px) [41]. When cells are exposed to conditions of increased
oxidative stress, such as exposure to PCN, their SOD and CAT activities increase to compensate [38];
however, it has been shown that SOD2 transcript levels decrease 8.5-fold in the presence of PCN [42],
indicating further studies are required. SOD exists in two intracellular forms, converting O2¨´ to
H2O2, thereby acting as the first protective mechanism against PCN induced oxidative stress [43].
Subsequently, the H2O2 generated from both PCN and SOD, is then in turn partially removed by
the enzyme CAT [44] or by the redox action of cellular thiol compounds, such as glutathione (GSH)
and thioredoxin [45,46]. PCN exposure decreases the activity of CAT, a peroxisomal enzyme and
an important component of the antioxidant defense system [38]. It has been postulated that this
ability of PCN is partially due to its consumption of catalase-associated NADPH resulting in increased
production of O2¨´ and H2O2 [10,38] and a subsequent cycle resulting in cellular damage and death.
A second protective mechanism against free radical damage is through the redox action of the
thiol compounds such as GSH [45], whereby free radicals are removed via a non-enzymatic reduction
with GSH. Conversely, the removal of hydroperoxides requires enzymatic catalysis by GSH-Px. Both of
these reactions lead to the generation of glutathione disulfide (GSSG, or oxidized glutathione), which
is then in turn reduced back to GSH by glutathione reductase [47]. PCN has been suggested to directly
oxidize GSH, thereby promoting PCN-mediated ROS formation and subsequent oxidative stress [11].
Furthermore, PCN produces a concentration-dependent decrease in GSH levels through its ability
to increase in H2O2 levels, as described earlier [11]. During this process, PCN returns to its reduced
form, again capable of creating ROS [11]. Treatment with exogenous GSH or GSH precursors, such as
N-acetylcysteine (NAC), is known to provide protection against PCN-induced oxidative injury [48].
This further implicates PCN exposure in cellular damage resulting from oxidative stress.
Recently, the effects of PCN-induced free radical formation on various cell signaling pathways
have been assessed in a number of studies. It has been reported that PCN induced the oxidative
stress-dependent induction of MUC2 and MUC5AC, both genes encoding for mucin secretion,
through a mechanism involving epidermal growth factor receptor/extracellular signal-regulated
kinase (EGFR/ERK) activation. This resulted in increased mucous secretion in the respiratory tract
further aiding in the colonization of the airways by P. aeruginosa [39]. The underlying EGFR signaling
mechanism in this experimental model remains to be fully elucidated. However, it has been proposed
that EGFR may be either activated directly through ROS, pro-inflammatory cytokines, or by EGFR
ligands [39]. A subsequent study found that PCN rapidly increased ERK1/2 phosphorylation however
it was shown PCN-induced cytotoxicity was independent of c-Jun N-terminal kinases (JNK) and p38
mitogen-activated protein kinases (MAPK). These results indicate that PCN-induced oxidative stress
is independent of ERK1/2 signaling, suggesting that further studies are needed to elucidate the effects
of PCN on signaling pathways [49].
The extensive studies on the free radical effects of PCN show the relevance and importance of
this property to the virulence and pathogenicity of P. aeruginosa. Further studies are needed, however,
to fully elucidate the cell signaling pathways involved in these effects.
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3. Manifestations of PCN Exposure
Studies have been undertaken assessing the impact of PCN on respiratory, urological, neurological,
cardiovascular, and hepatic models, both in vitro and in vivo [27–31,33,48,50,51], with the majority
of these studies undertaken in in vitro systems. These studies have highlighted the diverse range
of effects that PCN has on the host, including pro-inflammatory [11,12,33] and immunomodulating
properties [33]. Further to these effects, the presence of PCN in cellular systems places them under
increased oxidative stress, resulting in cellular death [12].
3.1. Inflammatory Effects of PCN
Numerous studies have investigated the effects of PCN on the host immune function in in vivo
and in vitro studies. However, to date, no studies have assessed the inflammatory effects in
humans [26,37,52]. This review will outline the in vivo and in vitro inflammatory effects below.
In vivo studies have predominantly investigated immunological effects in the respiratory tract
of animals and will be discussed in further detail below. PCN has, however, been shown to alter the
expression and release of a number of cytokines in vitro [26,37,52]. PCN has been shown to inhibit the
release of interleukin (IL)-2 [37,52,53] and decreases the expression of IL-2 receptors on T-cells [34,53].
This subsequently leads to the decrease in the secretion of immunoglobulin by B-lymphocytes [37]
and inhibition of lymphocyte proliferation [21,32,34], resulting in a decreased immune response and,
thereby, potentially protecting P. aeruginosa from the immune system. PCN concentrations as low as
40 µM (0.08 mg/mL) have been shown to be toxic to lymphocytes, which are consistent with reported
physiological concentrations [54].
In addition to effects on lymphocytes, PCN also has toxic effects on neutrophils, predominantly
through apoptotic pathways [55]. Neutrophils play an important role in the pathogenesis of CF and
possibly other respiratory disorders with increased numbers observed in the tissue of lungs [56] with
the influx of neutrophils resulting in an increase in inflammation [50]. PCN attracts neutrophils through
the production of two neutrophil chemotaxins, IL-8 and leukotriene B4 (LTB4) [52], and induces
a rapid and selective apoptosis of neutrophils at concentrations that are found in the sputum of
CF patients [57]. PCN exposure has been shown to increase in IL-8 levels [52], through a signal
transduction pathway [26]. This pathway includes oxidants, protein tyrosine kinases (PTKs),
and MAPKs [26]. Recent studies investigated the signaling pathways further and found PCN increased
IL-8 secretion in a time and concentration-dependent manner and suggest the phosphokinase C
(PKC), p38, and ERK MAPKs, and nuclear factor-kappa B (NF-κB) are involved in mediating the
increases [58,59]. Neutrophil apoptosis [23,37,55,60,61] and impairment of neutrophil-mediated
host defenses are other effects PCN plays on neutrophils [61]. Apoptosis after exposure to PCN
is time- and concentration-dependent, occurring at concentrations of 10 µM (2.11 µg/mL) and above.
Concentrations of 50 µM (10.55 µg/mL) PCN induce a 10-fold increase in neutrophil apoptosis at
5 h [60]. This effect is thought to be mediated through the increase of reactive oxygen intermediates
and a decrease in intracellular cyclic AMP (cAMP) concentration [60]. A recent study identified that
one such potential mechanism involving PCN induction of mitochondrial ROS which subsequently
induces neutrophil death and apoptosis via mitochondrial acid sphingomyelinase [62].
Neutrophils are additionally responsible for the release of large amounts of elastase and other
proteases [56,63], as well as various oxidants and enzymes [64], all contributing factors to the
progressive lung destruction experienced by CF and bronchiectasis patients [63,65]. The proteases
released by neutrophils overwhelm the local host defenses, including α-1 antitrypsin and leukocyte
protease inhibitor, important in protecting tissue from proteases released from inflammatory cells,
leading to increased risk of chronic infection [63,65]. To further complicate the issue, PCN inactivates
α1-antitrypsin [36], resulting in an imbalance of protease-antiprotease activity in the airways of CF and
bronchiectasis patients [36], and ultimately results in increased levels of human neutrophil elastase [66].
Human neutrophil elastase is responsible for the breakdown of lung tissue and ultimately contributes
to the pathogenesis of CF [36] and other respiratory disorders. Neutrophils also play an important role
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later in the inflammatory response with their breakdown producing large amounts of high molecular
weight DNA. High molecular weight DNA increases the viscosity of the mucous and ultimately
contributes to decreased mucociliary clearance [67]. Under inflammatory conditions associated with
the P. aeruginosa infection, stimulated neutrophils secrete myeloperoxidase (MPO) and H2O2, both of
which are essential components of a peroxidase system and are known causes of oxidative stress [12].
Bianchi et al. (2008) showed that PCN impaired macrophage engulfment of apoptotic cells as a result of
intracellular ROS generation and modulation of small GTPase signaling [68]. This identifies a novel and
potentially important mechanism by which pathogens could disrupt efficient clearance of inflammatory
cells, increasing host tissue injury [68].
PCN has been shown to exert various other effects on inflammation including its ability to
decrease Regulated upon Activation, Normal T Expressed and Secreted (RANTES) [52], an important
chemokine involved in the chemoattraction of macrophages and CD4+ memory T-cells [69]. This may
alter the normal immune response, leading to reduced clearance of P. aeruginosa and, ultimately,
further contributing to tissue damage. Interestingly, PCN has been shown to have little direct effect on
inducing monokines, including IL-1 and tumor necrosis factor (TNF) by monocytes, but significantly
enhances their lipopolysaccharide (LPS)-stimulated production [54]. This is of particular importance
in P. aeruginosa infection, due to the bacterium’s ability to produce LPS. These effects lead to the
suppression of defense mechanisms and enhance harmful inflammatory reactions of the host during
infection with P. aeruginosa [54], potentially resulting in increased virulence and colonization.
3.2. The Effects of PCN on the Respiratory System
The respiratory effects of PCN have been extensively studied due to the high prevalence of
pseudomonal infections in respiratory conditions such as CF and bronchiectasis [21]. The damage to
the respiratory system can be primarily attributed to the free radical and inflammatory effects of PCN
outlined above. Furthermore, significant concentrations of PCN have been detected in the sputum sol
of colonized patients, with concentrations up to 130 µM [21]. The respiratory effects of PCN have been
evaluated in in vitro, in vivo and human studies and are outlined below.
A limited number of human studies have evaluated the effects of PCN on the respiratory
tract [21,70]. The sol phase isolated from patients with colonization with P. aeruginosa with detectable
concentrations of PCN was shown to significantly slow ciliary beating in all nine cases [21].
Furthermore, in eight of the nine cases in this study, ciliary dyskinesia, ciliary stasis, and epithelial
disruption occurred, suggesting a concentration-dependent mechanism may be responsible [21].
A second human study investigated the effects of sputum PCN concentration on lung function in
48 CF patients [70]. An inverse correlation was observed between sputum PCN concentration and
lung function providing further evidence of the destructive nature of PCN [70].
In addition to the human studies, a limited number of in vivo studies have been conducted
evaluating the effects of PCN on the respiratory tract [23,50,71,72]. PCN exposure has been shown to
induce several negative changes in the respiratory tract predominantly through its pro-inflammatory
and pro-oxidant effects [23,50,71,72]. Several studies have shown PCN exposure to induce neutrophil
influx into the lungs after local instillation into the respiratory tract suggestive that PCN plays a role in
the mediation of goblet cell hyperplasia and pneumonia development [23,50,71,72]. This was shown to
occur as early as 3 h and persist for 24 h post-PCN exposure and occurred in a concentration-dependent
manner [23,71]. Increases in murine neutrophil chemokines keratinocyte chemoattractant (KC),
macrophage inflammatory protein (MIP-2), and intracellular adhesion molecule 1 (ICAM-1), all of
which play a role in the migration of neutrophils, were observed after animals were treated into the
airways with 100 µM of PCN [71].
A recent study suggests that PCN suppresses FoxA2, a transcriptional repressor of goblet cell
hyperplasia and mucous production, via the upregulation of Stat6 and EGFR [72]. It is suggested that
this may occur through either a pro-inflammatory response mediated through a Th2 response and Stat6
signaling or the production of ROS and MEK1/2 and ERK1/2 signaling, both known to downregulate
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the expression of FoxA2 [72]. Furthermore, significant changes to tracheal mucous velocity have been
observed with relatively low doses of PCN (600 ng) occurring 3 h post-PCN exposure and no recovery
observed [73]. These studies suggest that PCN plays an important role in the production of mucous in
the lungs of infected patients.
The majority of studies investigating the effects of PCN in respiratory cells have been done in
in vitro models and have evaluated the effects of PCN on oxidative stress and inflammatory-mediated
damage. One such study showed that when both A549 and primary NHBE respiratory cells were
exposed to ě5 µM concentrations of PCN over at least 12 h, the activity of catalase decreased
significantly [74]. Similar to SOD, CAT transcription appears to also be adversely affected by
PCN-mediated ROS formation. In the presence of PCN, CAT mRNA levels were decreased in human
bronchial H292 cells [42], suggesting PCN may negatively affect both expression and function of
cellular antioxidant defense mechanisms. Additionally, Muller et al. (2006) found that exposure
of A549 cells to PCN resulted in the formation of H2O2 in a dose-dependent manner and that the
senescence-inducing effect of PCN could be overcome in the presence of glutathione at concentrations
of 0.5 mM above [34].
Recently, oxidative stress has been causally linked to PCN-induced toxicity in human respiratory
A549 cells [48]. It was found that supplementation of the antioxidant NAC prior to PCN
exposure protected cells from oxidative stress and cytotoxicity. PCN is known to induce oxidative
stress-dependent mucin hypersecretion in bronchial epithelial cells [42]. Overproduction of mucin
glycoproteins prevents airway clearance and provides a favorable environment for P. aeruginosa
colonization in CF airways [39].
Investigations into the effects of PCN on pro-inflammatory mediators and the chemotaxis
of polymorphonuclear (PMN) cells have been undertaken [50]. After 24 hours of PCN
exposure, IL-8 concentrations produced by alveolar macrophages significantly increased suggesting
a pro-inflammatory response [50]. Furthermore, chemotactic activity was observed in PMN cells
exposed to PCN for 24 h [50]. These results suggested that the observed inflammatory response
post-PCN exposure was mediated through the production of chemotactic factors [50]. A second study
investigated the effects of 48 h PCN exposure on surface ICAM-1, finding that exposure increased
its expression in a concentration-dependent mechanism [71]. Furthermore, it was shown that PCN
synergizes with IL-1β and tumor necrosis factor alpha (TNF-α) in increasing ICAM-1 however this
effect can be blocked by the addition of NAC in a concentration-dependent manner [71].
The studies outlined above highlight the importance of the free radical effects PCN produces and
highlights the importance of this mechanism as major cause of the pathogenicity of this compound.
3.3. The Effects of PCN on the Urological Systems
P. aeruginosa is implicated in a large percentage of nosocomial urinary tract infections, particularly
in patients with urethral catheters, and is commonly associated with high levels of antibiotic
resistance [2]. Chronic and recurrent urinary tract infections are, therefore, common; a characteristic
attributed to their ability to form biofilms on the surface of urinary catheters, adhere to the urothelium
and secrete an array of virulence factors. Although no literature to date specifically assess levels of
PCN in the bladder, up to 39 µM PCN has been detected in vitro from urinary isolates and Al-Ani et al.
(1986) reported that urinary pseudomonal isolates produced more PCN than isolates form other clinical
specimens tested [75]. To date studies on the effects of PCN on the urological system have only been
undertaken in vitro and are outlined below.
A recent study by McDermott et al. (2012) was the first to assess the effects of PCN on the urothelial
cells. They reported that PCN significantly reduced RT4 urothelial cell viability at concentrations
of 25 µM and greater [28]. Furthermore PCN induced cellular senescence in RT4 urothelial cells at
concentrations of 25–50 µM, demonstrated by increased SA-β-gal expression coinciding with observed
changes in morphological characteristics. Induction of cellular senescence by PCN inhibits the ability
of wound tissue to repair [76], suggesting a possible role for senescence in preventing urothelial repair
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during urinary tract infection. Reduction in urothelial barrier function as a result of PCN exposure
may, therefore, contribute to recurrent infection. In contrast, 100 µM PCN showed no significant
effect on SA-β-gal expression, however, increased caspase-3 activity suggesting cellular apoptosis [28].
Therefore, it is likely that the effect of PCN on urothelial function is concentration-dependent.
This study also provided evidence that PCN reduced baseline and stimulated adenosine
triphosphate (ATP) release [28]. This suggests that despite the role of ATP in mediating perception of
pain, pain associated with P. aeruginosa urinary tract infections may not be associated with enhanced
urothelial ATP release.
A second study on the effects of PCN on the urinary tract investigated the inflammatory
effects. It was found that PCN increased prostaglandin E2 (PGE2) production in RT4 urothelial
cells in a concentration-dependent manner, with statistically significant increases observed at 100 µM.
Furthermore, it was found that 100 µM of PCN increased IL-6 levels in the same cell line [27]. This study
suggested that PCN-induced increases in IL-6 in urothelial cells may contribute to local urinary tract
symptoms and highlights the possible inflammatory contribution of PCN in urinary tract infections
caused by P. aeruginosa [27].
3.4. The Effects of PCN on the Central Nervous System
Infection of the CNS with P. aeruginosa, though rare, is associated with high mortality. There is
currently limited evidence to support mechanisms underlying this toxicity, with all available studies
currently using in vitro models. A preliminary study by McFarland et al. (2012) was the first to
determine the effect of PCN in a neurological model, identifying that PCN treatment induced toxicity in
1321N1 astrocytoma cells, and correlated with the formation of acidic vesicular organelles (AVOs) [30].
This finding is consistent with induction of macroautophagy—a conserved lysosomal degradation
pathway involving the recycling of cellular proteins and organelles. The addition of 3-methyladenine,
an inhibitor of macroautophagy through inhibition of class III phosphoinositide, provided complete
protection from PCN toxicity, further suggesting that PCN may interfere with the inherent autophagic
processes of these cells. Furthermore, McFarland et al. (2012) identified that whilst PCN still induced
oxidative stress, apoptosis, and cellular senescence in astrocytoma cells, these appeared to occur
secondary to AVO formation [30].
A second follow-up study, comparing the effects of PCN on both 1321N1 astrocytoma cells and
SH-SY5Y neuroblastoma cells, found SH-SY5Y cells to be significantly more resistant to the toxic
effects of PCN [31]. Of particular interest, it was shown that 3-methyladenine, previously shown to
be protective against PCN-induced toxicity in 1321N1 astrocytoma cells, had a paradoxical effect in
SH-SY5Y neuroblastoma cells, decreasing the cells’ resistance to PCN toxicity. Additionally, it was
observed that PCN exposure in both cell lines resulted in similar increases in inflammatory mediators
as with other in vitro models [27]. Significant PCN-induced increases in IL-8, PGE2 and were observed
with both cell lines, implicating PCN-induced inflammation as a possible contributing factor to the
pathophysiology of CNS pseudomonal infections. This study established that the toxic effects of
PCN in these cell lines was independent of oxidative stress, hence further supporting the role of
autophagy-mediated death in PCN-treated 1321N1 and SH-SY5Y cells [31]. Further investigation is
required to fully establish the mechanisms of PCN in in vitro neurotoxicity and, in particular, in vivo
studies are needed.
3.5. The Effects of PCN on the Vascular System
Few studies have evaluated the effects of PCN on the vascular system to date, and those available
are limited to in vitro studies [29,77,78]. However, P. aeruginosa is a rare cause of infective endocarditis
and is seen primarily in injection drug users and patients undergoing cardiac procedures [3–6].
Therefore PCN potentially has an effect on the function of the vascular system in these patients.
Additionally, given the unconfirmed status of diffusibility of PCN into systemic circulation from
local infections, it is possible that vascular effects may be observed in patients, particularly those
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with prolonged exposure, such as CF. Vascular manifestations may also arise from P. aeruginosa
sepsis, a life-threatening systemic infection that is becoming more prevalent in society [79]. PCN,
at physiologically relevant concentrations, has been shown to inhibit vasorelaxation of porcine coronary
arteries via both nitric oxide-dependent [29,77] and -independent mechanisms [29]. A recent study
has shown that CF patients experience endothelial dysfunction [78] which may be further exacerbated
through exposure to PCN. Furthermore, these effects in combination with the effects of PCN on NO
suggest that exposure may relate to an increased risk of hypertension, however, further in vivo and
human studies are needed to fully investigate this possible effect.
3.6. The Effects of PCN on the Hepatic System
To date, only a small number of in vivo studies have been undertaken assessing the effects of PCN
on hepatic function [33,51]. PCN was shown to significantly alter the morphology of liver sinusoidal
endothelial cells (LSEC) including a reduction in the porosity of these cells [33]. Protection from
these changes in morphology was however achieved with the addition of CAT, suggesting a free
radical-mediated mechanism of toxicity [33]. A subsequent study however further investigated the
mechanism by which PCN elicited its toxic response and found it to be independent of free radical
damage suggesting a novel mechanism of PCN-induced pathogenesis in the liver [51]. The effects
of PCN on the liver may result, clinically, in changes to the metabolism of hepatically-cleared drugs,
posing potentially serious implications for patients. These effects, however, have not been studied,
but would provide useful information if studied in the future.
3.7. Endocrine Effects of PCN
Limited in vitro studies have been undertaken assessing the effects of PCN on the development
of diabetes to date. PCN has been shown to be able to deplete cellular ATP and inhibit aconitase, a key
component of the Krebs cycle [38]. Aconitase has been long shown to play a role in the development
of diabetes, with a decrease in its activity seen in both alloxan and genetic diabetes [80–83]. Given the
high incidence of both diabetes and infection with PCN-producing P. aeruingona organisms in CF, this
mechanism may provide an insight into the associated pathophysiology, however, further studies
are needed to confirm these effects. A second potential mechanism by which PCN may impact
on the development of diabetes, in CF patients in particular, is through oxidative stress pathways.
PCN, as outlined previously, is a highly redox-active compound that causes many of its cytotoxic
effects through oxidative stress. Studies have shown that oxidative stress, in particular superoxide,
may play an important role in the onset of diabetes and have been reviewed extensively in the past
(reviewed in [84]). Given the ability of PCN to generate superoxide [85] it is possible that, in chronic
exposure, that PCN may contribute to the onset of diabetes via this mechanism. A third possible
mechanism by which PCN may contribute to diabetes associated with CF is through its inactivation
of V-ATPase. V-ATPase has been shown to have numerous biologically functions and 1 subunit
has been shown to be of importance in the release of insulin from pancreatic β-cells [86]. PCN
inhibits V-ATPase by the generation of the ROS, predominantly H2O2 and is directly correlated to
its concentration. Therefore, increasing levels of PCN caused a corresponding decrease in V-ATPase
activity in a concentration-dependent manner [37,87]. Given the potential effects of V-ATPase, further
studies into the effects of PCN on specific isoforms of the enzymes are warranted. The possible
mechanisms of PCN action in the pathogenesis of diabetes in susceptible patients, as outlined above
are plausible. However, further studies are needed to explore these effects.
3.8. Role of PCN in Normal Monitored Cellular Activities
In vivo studies, using Caenorhabditis elegans as a model, have shown phenazines produced
by P. aeruginosa to mediate its toxic effects through the generation of ROS [88]. A further study
investigating the cellular responses of C. elegans to pathogenic P. aeruginosa, found that surveillance
pathways controlling core cellular activities of the organism allow detection of pathogens with the
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capability to produce virulence factors and undermine vital host functions [89]. This, then, resulted
in an alteration of behavior, namely pathogen-avoidance behaviour [89]. Disruption to the core
cellular processes associated with aversion behavior were attributed to involvement of the JNK MAPK
pathway triggered by an intracellular stress response [89]. Given PCN’s nature to induce mitochondrial
oxidative stress, further investigations into its mitochondrial effects have been described [90,91]. PCN
was shown to disturb cellular responses in C. elegans that resulted in aversion behavior and was found
to be mediated through a mitochondrial pathway resulting in unfolded protein responses [90,91].
These studies further suggest that PCN elicits its toxic cellular effects through the production of ROS,
particularly targeting the mitochondria of cells and may be a result of protein unfolding when exposed
to PCN.
4. Future Directions
As highlighted in the studies outlined above, PCN has been shown to impact on the cellular
function of many body systems. However, these are predominantly limited to in vitro studies.
These studies have suggested that PCN elicits its toxic effects through ROS and inflammatory mediated
pathways. This provides us with the basic mechanisms of cellular toxicity associated with PCN
exposure and highlights possible pathways to target in the search for therapies to minimize toxicities
associated with P. aeruginosa infection. Further studies assessing the observed effects are warranted
in vivo and in humans, particularly given the studies suggesting that aversion behavior exists in
C. elegans exposed to PCN. To date very few in vivo studies have investigated the effects of PCN,
however, within the limited number of studies undertaken significant cellular damage was reported.
Given the highly toxic nature of PCN, future studies investigating strategies to minimize cellular
damage associated with PCN exposure should be investigated. Such strategies include modifying
either the production of PCN by P. aeruginosa or by preventing the toxic effects using pharmacological
modulators. To date, there have been a small number of studies assessing the effects of pharmacological
agents on the production of PCN from P. aeruginosa in vitro. However, these have not been assessed
in vivo [92–98]. Furthermore, numerous compounds with antioxidant properties have been assessed
for their protective properties in vitro, however these have not been evaluated for their effectiveness
in in vivo studies [48]. Both of these strategies have provided promising evidence to suggest that they
may be beneficial in protecting against PCN-induced cellular toxicity.
5. Conclusions
Numerous studies have been undertaken assessing the cellular effects of PCN exposure in various
body systems, both in vitro and in vivo. A diverse range of toxic effects have been observed in animals
and cells exposed to PCN which have been shown to be predominantly mediated by free radical
and pro-inflammatory cytokine production. Given the nature of pseudomonal infections, the effects
of PCN on the respiratory tract are the most widely studied phenomenon. Recent in vitro studies
have, however, shown that PCN has deleterious effects on cells in numerous other body systems,
including the CNS, the urolological and the vascular system, with mechanisms other than oxidative
stress implicated in a number of circumstances. In light of this, further studies investigating these
effects in vivo and, ultimately, in a human population infected with PCN-producing P. aeruginosa are
warranted to assess the impact of this exposure, physiologically.
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